Seeking Alpha


Send Message
View as an RSS Feed
View candooman's Comments BY TICKER:
Latest  |  Highest rated
  • Athersys: Where Is The Run Up Before The Binary Event? [View article]
    Multistem is not meant to be a cure; it is meant to stop further damage to the brain from the spleen's reaction to the stroke. Brain plasticity will repair the damage but the results will depend on how much damage has been done. The idea here is to limit the damage so the brain will and can repair itself and get back close to what it was before.

    It is possible that when Multistem is applied in the 6-24 time frame, the spleen reaction can be suppressed so that there is no further damage. tPA when applied within 3-4 hours works most of the time.... but not all the time. So, it is also possible that if multistem is applied after 6 hours, the damage to the brain can be significantly limited. Should this be shown in additional trials, Multistem could be made part of the standard treatment for stroke patients.

    Knowing the Japanese knack for improving on other people's inventions, Chugai will try to do this.
    Apr 20, 2015. 11:26 AM | 1 Like Like |Link to Comment
  • Athersys: Where Is The Run Up Before The Binary Event? [View article]
    There should be a Phase 2b trial for the 6 to 36 hour window to prove efficacy. I suggest Ph 2b because it will require only a small group of less than a hundred (including placebo). Additionally, the trial will be short in duration - 90 days.

    The safety and tolerability has already been established. ATHX management should design a Ph 2b trial and have it approved by FDA. After the results are in, hopefully, a lot better than Ph 2, the Ph 3 trials can be designed based on the results.

    The published results left out much details, like the number of patients who got the higher dosage in less than 36 hours. The data should be further divided between 24 and 36 hours. I envision Multistem being effective when applied between 6 and 24 hours and will be the new standard treatment for ischemic stroke.
    Apr 20, 2015. 11:02 AM | 2 Likes Like |Link to Comment
  • Phase 2 ALS trial of Neuralstem's NSI-566 meets safety endpoints and shows 47% response rate [View news story]
    Bause, As pointed out in the numbers stated in the article, the slope of decline of the responders is almost flat (their condition did not worsen) whereas the slope of decline for the non-responders was significantly lower -- their health got worse...... just like those who have the decease......(I cannot use the word treated because there is no treatment).
    Mar 12, 2015. 05:25 PM | Likes Like |Link to Comment
  • Will Neuralstem Phase II Results Pave The Road To A Stem Cell Cure For ALS? [View article]
    Feb 19, 2015. 10:34 AM | Likes Like |Link to Comment
  • Sirius XM Earnings Analysis: By The Numbers [View article]
    These people whose average cost is in the 10 to 15 cents bought their shares somewhere between February and May of 2009. I know, some of my holdings were from those wonderful times.... and still holding. No embellishments here, no Brian Williams here.
    Feb 9, 2015. 03:31 PM | Likes Like |Link to Comment
  • InVivo Therapeutics: Long Idea Playing Out With Room To Run [View article]
    Correction: CUR is in Phase 1 of SCI where cells are dropped in on an open spinal cord. CUR is in Ph 2 on ALS Trials, delivering cells via lumbar and cervical injections consisting of millions of cells. By the time NVIV is ready to start trials on scaffold+cells, CUR should have results in their Ph 1 SCI trials. On Monday, Feb 9th, CUR reports on progress in their trials at a medical conference.
    Feb 3, 2015. 12:04 PM | Likes Like |Link to Comment
  • InVivo Therapeutics: Long Idea Playing Out With Room To Run [View article]
    CUR is also treating spinal cord injuries (between 1-2 years post injury) using their own line of stem cells. They are much further along (deep into Ph 2 trials) than STEM in trials and fro their record, they are a much better fit with NVIV as partners.
    Feb 3, 2015. 07:30 AM | 2 Likes Like |Link to Comment
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    This is too small a trial to say that since it just slows down the disease progression, it is not good. The trial was done in 3 cohorts. The results presented were for the entire trial. The results for the higher dosed patients were not discussed (one person in the Q&A asked this question and did not get an answer). Could it have been that the progression of the disease was stopped ... or maybe even slightly reversed? Could a multiple dosage reverse the progression of ALS? It is too early to make definitive conclusions.
    Jan 7, 2015. 05:20 PM | 1 Like Like |Link to Comment
  • A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results [View article]
    CUR reports on results on Tue Jan 13th, 9 AM. We will see, perhaps, if BCLI is better than CUR, or, is it an apple and orange comparison -- both taste good!
    Jan 7, 2015. 05:11 PM | Likes Like |Link to Comment
  • Sirius Is Seriously Going Higher [View article]
    I agree with you SF. Lowest I got was 0.08 and a lot more between 0.11 and 0.15. Got more later to average out in the mid 0.40s. Fortunately I only have a couple hundreds at $4+ from 2008 -- pre-Feb 2009.

    As you noted, very few shares were traded at 0.05.
    Jan 2, 2015. 01:27 PM | Likes Like |Link to Comment
  • Sirius Is Seriously Going Higher [View article]
    If not for Malone, err, err, err Ergen better? He would have gotten SIRI for nothing and thrown us shareholders all out. Yup, Malone got a good chunk of SIRI but then, we got a lot of capital gains.... so thanks Mr Malone.
    Jan 2, 2015. 01:12 PM | 3 Likes Like |Link to Comment
  • Sirius XM Short Interest Continues To Decline [View article]
    Good article CN! Thanks.
    Here is to a Prosperous New Year and a rising SIRIUSXM stock!
    Initial December car sales reports shows a good jump.
    Dec 30, 2014. 10:59 AM | Likes Like |Link to Comment
  • Cell Therapy 2015: With Maturity Comes Promise [View article]
    OCAT (formerly ACTC) is the only company with FDA approved treatment using hESC. It has successfully finished Ph1/2 AMD and SMD trials with strong indications of efficacy at the higher cell dosage and is about to start Ph 2. I believe they have FDA approval to treat AMD of younger patients who most likely will get better results than their trial patients who were in their 80s and have had AMD for many many years.

    I do not understand why the author did not mention this pioneering company.
    Dec 24, 2014. 12:55 PM | Likes Like |Link to Comment
  • Sirius XM: Thoughts On Manipulation [View article]
    Thank you Prof Faulkner, for providing a clear explanation of the stock price staying in a narrow range in spite of hundreds of millions of buybacks..... and how Malone was able to control his takeover of SIRI, all without costing him too much money. It was a big puzzle to me. After December 1st, will we see much lower number of shorts?
    Nov 28, 2014. 05:44 PM | 1 Like Like |Link to Comment
  • Athersys Could Benefit Immensely From Japan Reimbursement On Stroke [View article]
    All companies that treat diseases with cells will benefit from this new Japanese law. Some companies are in a more advanced state of Phase II trials in the US and have shown efficacy in their completed Phase I trials. A couple of companies that come to mind that will benefit from this new Japanese law, should they chose to do some trials in Japan are OCAT and CUR. Because of the extra cost and limited resources, they may opt in only after they have received FDA approvals, which will make it easy to enter the Japanese market.
    Nov 26, 2014. 12:48 PM | 3 Likes Like |Link to Comment